Intranasal Therapeutics, Inc.

Nasally delivered pharmaceuticals developer names two new members to its board of directors

Published in Lab Law Weekly, November 18th, 2005

Intranasal Therapeutics, Inc., (ITI) announced that the company has recently named two new members to its board of directors: Lisa Giles, president and founder of Giles & Associates Consultancy, Inc., and Paul Ashton, PhD., president and CEO of Control Delivery Systems.

"Giles and Ashton bring valuable perspective and experience to our company," said Edwin Cohen, founder and chairman of the board of ITI. "We look forward to their guidance as ITI continues to achieve new milestones as an integrated specialty pharmaceutical company developing innovative new nasal drug therapies."

Giles founded Giles & Associates Consultancy, Inc., (GAC) in 2000. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Lab Law Weekly

Source: Lab Law Weekly (2005-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry